Evidence map›Paper›PMID 31367877›Full record

Trial reportDigestive diseases and sciences2020

Fecal Microbiota Transplant via Endoscopic Delivering Through Small Intestine and Colon: No Difference for Crohn's Disease.

Zhenyu Yang, Chibin Bu, Wei Yuan, Zhaohua Shen, Yongsheng Quan, Shuai Wu, Changxin Zhu, Xiaoyan Wang

Abstract readComparative StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Digestive diseases and sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Current perspectives on fecal microbiota transplantation in inflammatory bowel disease.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2024
    Review
  14. Review
  15. Review
  16. Review
  17. Fecal transplantation for treatment of inflammatory bowel disease.The Cochrane database of systematic reviews · 2023
    Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhenyu YangDepartment of Gastroenterology, Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Chibin BuDepartment of Gastroenterology, Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Wei YuanDepartment of Gastroenterology, Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Zhaohua ShenDepartment of Gastroenterology, Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Yongsheng QuanDepartment of Gastroenterology, Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Shuai WuDepartment of Gastroenterology, Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Changxin ZhuDepartment of Gastroenterology, Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Xiaoyan WangDepartment of Gastroenterology, Third Xiangya Hospital, Central South University, Changsha, Hunan, China. wxy20011@163.com.

Funding

National Natural Science Foundation of China 81272736
6 · The paper itself

Abstract

BACKGROUND AND

aimsCrohn's disease (CD) is a chronic inflammatory bowel disorder associated with intestinal dysbiosis. This study aimed to determine the efficacy and safety of different methods of fecal microbiota transplantation (FMT), a potential therapy for CD.

methodsPatients with CD were randomized to receive FMT by gastroscopy or colonoscopy; a second transplantation was performed 1 week later. Patients were assessed by clinical evaluation and serum testing (at weeks 1, 2, 4, 6, and 8) and endoscopy (8 weeks after transplantation). Fecal DNA was extracted and analyzed using the Illuminal sequencing platform.

resultsOf the 27 patients included in the study, clinical remission was achieved in 18 (66.7%); no significant difference was seen between the two methods. 76.9% of gastroscopy group patients and 64.3% of colonoscopy group patients experienced mild adverse events during or shortly after treatment. Microbiota diversity analyses showed that, in comparison with the donors, patients had lower operational taxonomic units (OTU; 117 vs. 258, p < 0.05) and Shannon diversity index (2.05 vs. 3.46, p < 0.05). The CD patients showed a significant increase in OTU and Shannon diversity index 2 weeks after FMT. In comparison with the donors, CD patients had lower levels of Bacteroides, Eubacterium, faecalibacterium, and Roseburia, and higher levels of Clostridium, Cronobacter, Fusobacterium, and Streptococcus.

conclusionsFMT was seen to be safe and effective in this cohort of patients with CD. No significant differences in clinical remission rate and adverse events were seen between the gastroscopy and colonoscopy groups. FMT was seen to increase the species richness in CD patients.

Indexed as

ColonoscopyFecal Microbiota TransplantationGastrointestinal MicrobiomeGastroscopyAdultChinaColonCrohn DiseaseDouble-Blind MethodDysbiosisFemaleHumansIntestine, SmallMaleMiddle AgedProspective StudiesClinical trialCrohn’s diseaseFecal microbiota transplantationIntestinal dysbacteriosis

Identifiers

PMID31367877

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.